Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.
Tam CS, Trotman J, Opat S, Stern JC, Allewelt H, By K, Novotny W, Huang J, Tedeschi A. Tam CS, et al. Among authors: opat s. Blood Adv. 2023 Jun 27;7(12):2884-2887. doi: 10.1182/bloodadvances.2022008990. Blood Adv. 2023. PMID: 36753605 Free PMC article. No abstract available.
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Tariq B, Ou YC, Stern JC, Mundra V, Wong Doo N, Walker P, Lewis KL, Lin C, Novotny W, Sahasranaman S, Opat S. Tariq B, et al. Among authors: opat s. Leuk Lymphoma. 2023 Feb;64(2):329-338. doi: 10.1080/10428194.2022.2150820. Epub 2022 Dec 8. Leuk Lymphoma. 2023. PMID: 36480811 Free article. Clinical Trial.
Reply to Y. Song et al.
Dimopoulos MA, Opat S, Treon SP, Tam CS. Dimopoulos MA, et al. Among authors: opat s. J Clin Oncol. 2024 Feb 1;42(4):482-484. doi: 10.1200/JCO.23.02162. Epub 2023 Dec 4. J Clin Oncol. 2024. PMID: 38048515 No abstract available.
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, García-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyż J, Fernández De Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Wu B, Yu Y, Shen Z, Chan WY, Schneider J, Allewelt H, Cohen A, Dimopoulos MA. Tam CS, et al. Among authors: opat s. Blood Adv. 2024 Apr 9;8(7):1639-1650. doi: 10.1182/bloodadvances.2023010906. Blood Adv. 2024. PMID: 38315878 Free PMC article.
A drop of vitriol: microspherocytosis following sulphuric acid exposure.
Polizzotto MN, Shortt J, Opat SS, Cole-Sinclair MF. Polizzotto MN, et al. Among authors: opat ss. Br J Haematol. 2008 Mar;140(6):596. doi: 10.1111/j.1365-2141.2007.06938.x. Epub 2007 Dec 8. Br J Haematol. 2008. PMID: 18076709 Free article. No abstract available.
Oxidative haemolysis due to 'poppers'.
Shortt J, Polizzotto MN, Opat SS, Cole-Sinclair MF. Shortt J, et al. Among authors: opat ss. Br J Haematol. 2008 Jul;142(3):328. doi: 10.1111/j.1365-2141.2008.07150.x. Epub 2008 May 8. Br J Haematol. 2008. PMID: 18477042 Free article. No abstract available.
Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Patil S, Spencer A, Schwarer A, Avery S, Ritchie D, Opat S, Wei A, McLean C. Patil S, et al. Among authors: opat s. Leuk Lymphoma. 2009 Dec;50(12):1964-8. doi: 10.3109/10428190903288456. Leuk Lymphoma. 2009. PMID: 19860614
147 results